BioSpace News Archive

Business

CHMP Rejects Sarepta’s DMD Drug, Company Strikes Gene Therapy Deal with Myonexus Therapeutics

Shares of Sarepta Therapeutics slipped Thursday after the company announced a European Medicines Agency committee rejected Exondys 51 (eteplirsen), the company’s treatment for Duchenne Muscular dystrophy.

May 4, 2018

·

3 min read

·

Alex Keown

May 4th Research Roundup: Some of the Top Research Stories of the Week

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, such as newborn trauma and research to make the heart younger.

May 4, 2018

·

4 min read

·

Mark Terry

Woman celebrating her goals. Successful concept.

Drug Development

Bluebird bio Tapped for Humanitarian Award for Efforts to Develop Gene Therapy for Thalassemia

Bluebird has been chosen to receive the Cooley Anemia Foundation’s Humanitarian of the Year Award at its annual gala in June.

May 4, 2018

·

3 min read

·

Alex Keown

What is “Team Mindfulness” and How Can It Boost Workplace Performance?

A recently published study in the Academy of Management Journal suggests an innovative take on the well-established tradition of “mindfulness” that could have a positive impact on workplace productivity and job satisfaction.

May 4, 2018

·

2 min read

Drug Development

FDA Gives Portola Pharma’s Andexxa a Thumbs-up

The U.S. Food and Drug Administration (FDA) approved Portola Pharmaceuticals’ Andexxa, an antidote for blood thinners rivaroxaban and apixaban.

May 4, 2018

·

3 min read

·

Mark Terry

A woman with her head in her hands/Courtesy of Shu

Drug Development

Biotechs Develop Treatments Targeting Multiple Types of Mental Illness

Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.

May 4, 2018

·

3 min read

·

Alex Keown

Business

Merck and Moderna Expand Cancer Vaccine Partnership with Another $125 Million

Moderna Therapeutics and Merck expanded their 2016 collaboration deal to develop and commercialize personalized messenger RNA (mRNA) cancer vaccines. The new deal will include mRNA cancer vaccines that share antigens, including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.

May 4, 2018

·

3 min read

·

Mark Terry

$710M Gamble Fails as Celgene Terminates Two Phase

Business

Celgene Plans To File Second NDA for Ozanimod in 2019 Following FDA Rejection in February

Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.

May 4, 2018

·

3 min read

·

Alex Keown

Pharm Country

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

Boehringer Ingelheim announced that Praxbind® (idarucizumab) is now stocked in 3,200 hospitals in all 50 states.

May 4, 2018

·

12 min read

FDA

FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine

- Fast Track program is designed to facilitate development and expedite review of therapies and vaccines to address unmet health needs - There are no licensed vaccines for chikungunya prevention and no specific treatments

May 4, 2018

·

4 min read